NCT00454532View on ClinicalTrials.gov

A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

December 31, 2009

Conditions

Metastatic Breast Cancer

Interventions

DRUG

BZL101

Freeze dried powder mixed with liquid. Administered as a daily dose. Dosage to be determined in Phase 1 portion.

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bionovo

INDUSTRY

NCT00454532 - A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter